Genocea Biosciences, Inc.
- Jurisdiction
United States - ISIN
US3724274010 (GNCA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. Read full profile
Stock price
Fundamentals
- Net revenue
€232.62K - Gross margin
100.0% - EBIT
-€47.75M - EBIT margin
-20,525.2% - Net income
-€33.83M - Net margin
-14,542.6%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 10, 2022